Pentoxifylline Therapeutic Cheat Sheet
Pentoxifylline is a methyl-xanthine derivative traditionally used to treat symptoms of peripheral vascular disease and has emerged as a valuable therapeutic agent in dermatology for its anti-inflammatory and immunomodulatory properties. We continue our series, Therapeutic Cheat Sheet, with a closer look at pentoxifylline, which is FDA-approved for the treatment of intermittent claudication and is …
Pentoxifylline is a methyl-xanthine derivative traditionally used to treat symptoms of peripheral vascular disease and has emerged as a valuable therapeutic agent in dermatology for its anti-inflammatory and immunomodulatory properties. We continue our series, Therapeutic Cheat Sheet, with a closer look at pentoxifylline, which is FDA-approved for the treatment of intermittent claudication and is … 
Alopecia areata (AA) is a nonscarring alopecia driven by autoreactive cytotoxic CD8 T cells against hair follicle antigens. With an unpredictable clinical course, which can include alopecia totalis and universalis, AA can be debilitating to patients’ quality of life. Historically, glucocorticosteroids, cyclosporine, methotrexate, and azathioprine were used off-label for non-targeted immunosuppre … 
Metronidazole is a nitroimidazole with antiprotozoal, antibacterial, and anti-inflammatory properties and is available in oral and topical formulations. The diverse mechanisms of action of metronidazole have expanded its utility across various dermatologic conditions. Topical metronidazole is well tolerated and has demonstrated improvements in inflammatory papules and pustules of rosacea. We conti … 
Cemiplimab is a monoclonal antibody therapy that has emerged as a promising treatment option for certain types of advanced skin cancer. Specifically designed to target the programmed cell death protein 1 (PD-1) pathway, cemiplimab works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby unleashing the body's immune system to recognize and attack cancer cells. We con … 
Don’t forget about intralesional therapy as a treatment option for cutaneous malignancies, including non-melanoma and melanoma skin cancers, says Dr. Vishal A. Patel, director of cutaneous oncology at the GW Cancer Center. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Patel, who shared in which patients intralesional therapy may be … 